share_log

BioVie | 424B5: Prospectus

BioVie | 424B5: Prospectus

BioVie | 424B5:募資說明書
美股SEC公告 ·  09/25 17:25

Moomoo AI 已提取核心訊息

BioVie has issued a supplement to its prospectus, effectively suspending the continuous offering of its Class A common stock under a previously established Sales Agreement with Cantor Fitzgerald & Co. as of September 25, 2024. The supplement amends information from the original prospectus supplement dated January 19, 2024, and the prospectus dated August 28, 2023. Since the initial offering, BioVie has sold $6,446 worth of shares. The company's common stock, which is traded on the Nasdaq under the symbol BIVI, had a last reported sale price of $1.18 per share on September 24, 2024. The Sales Agreement remains effective, but no further sales will occur until a new prospectus supplement is filed with the Securities and Exchange Commission.
BioVie has issued a supplement to its prospectus, effectively suspending the continuous offering of its Class A common stock under a previously established Sales Agreement with Cantor Fitzgerald & Co. as of September 25, 2024. The supplement amends information from the original prospectus supplement dated January 19, 2024, and the prospectus dated August 28, 2023. Since the initial offering, BioVie has sold $6,446 worth of shares. The company's common stock, which is traded on the Nasdaq under the symbol BIVI, had a last reported sale price of $1.18 per share on September 24, 2024. The Sales Agreement remains effective, but no further sales will occur until a new prospectus supplement is filed with the Securities and Exchange Commission.
biovie已發佈了一份補充招股說明書,有效地暫停了其A類普通股的持續發行,根據之前與康富傑&Co.建立的銷售協議,截至2024年9月25日。該補充修訂了原始招股說明書補充,日期爲2024年1月19日,以及2023年8月28日的招股說明書的信息。自首次發行以來,biovie已售出價值6446美元的股份。該公司的普通股在納斯達克交易所以BIVI爲標的,截至2024年9月24日的最後報價爲每股1.18美元。銷售協議仍然有效,但在提交新的招股說明書補充給證券交易委員會之前,將不會發生進一步銷售。
biovie已發佈了一份補充招股說明書,有效地暫停了其A類普通股的持續發行,根據之前與康富傑&Co.建立的銷售協議,截至2024年9月25日。該補充修訂了原始招股說明書補充,日期爲2024年1月19日,以及2023年8月28日的招股說明書的信息。自首次發行以來,biovie已售出價值6446美元的股份。該公司的普通股在納斯達克交易所以BIVI爲標的,截至2024年9月24日的最後報價爲每股1.18美元。銷售協議仍然有效,但在提交新的招股說明書補充給證券交易委員會之前,將不會發生進一步銷售。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息